HM Payson & Co. Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

HM Payson & Co. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 370,617 shares of the company's stock after selling 13,456 shares during the period. HM Payson & Co.'s holdings in Johnson & Johnson were worth $53,599,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Knuff & Co LLC raised its holdings in shares of Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock valued at $1,534,000 after purchasing an additional 64 shares during the last quarter. Vertex Planning Partners LLC raised its holdings in shares of Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company's stock valued at $844,000 after purchasing an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management grew its position in Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock valued at $301,000 after buying an additional 66 shares during the period. Denali Advisors LLC grew its position in Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after buying an additional 67 shares during the period. Finally, Corepath Wealth Partners LLC grew its position in Johnson & Johnson by 3.7% during the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company's stock valued at $287,000 after buying an additional 70 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently issued reports on JNJ shares. Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Guggenheim boosted their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a "neutral" rating in a research report on Monday, February 3rd. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Finally, Raymond James dropped their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $171.33.

Remove Ads

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $166.81 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a fifty day moving average price of $152.95 and a 200 day moving average price of $156.28. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a market cap of $401.61 billion, a price-to-earnings ratio of 25.08, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the business earned $2.29 earnings per share. Johnson & Johnson's revenue for the quarter was up 5.3% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.